Amiloride selectively inhibits the urokinase-type plasminogen activator.
about
(4-aminomethyl)phenylguanidine derivatives as nonpeptidic highly selective inhibitors of human urokinaseRole of the TMPRSS2-ERG gene fusion in prostate cancerExpression pattern of the urokinase-plasminogen activator system in rat DS-sarcoma: role of oxygenation status and tumour sizeCharacterization of plasminogen system on rat yolk sac carcinoma (L2) cellsExtracellular alpha 6 integrin cleavage by urokinase-type plasminogen activator in human prostate cancerThe very low density lipoprotein receptor regulates urokinase receptor catabolism and breast cancer cell motility in vitro.Embryonic fibroblasts that are genetically deficient in low density lipoprotein receptor-related protein demonstrate increased activity of the urokinase receptor system and accelerated migration on vitronectin.Plasmin in nephrotic urine activates the epithelial sodium channelEffect of Poria cocos on Puromycin Aminonucleoside-Induced Nephrotic Syndrome in RatsCancer treatment with inhibitors of urokinase-type plasminogen activator and plasmin.Extracellular proteolysis in the adult murine brainAnti-tumour/metastasis effects of the potassium-sparing diuretic amiloride: an orally active anti-cancer drug waiting for its call-of-duty?Differential protease expression by cutaneous squamous and basal cell carcinomas.Expression of SPARC during development of the chicken chorioallantoic membrane: evidence for regulated proteolysis in vivo.Interference with the urokinase plasminogen activator system: a promising therapy concept for solid tumours.The plasminogen activation system modulates differently adipogenesis and myogenesis of embryonic stem cells.The NuRD chromatin-remodeling enzyme CHD4 promotes embryonic vascular integrity by transcriptionally regulating extracellular matrix proteolysis.Amiloride improves locomotor recovery after spinal cord injury.Regulation of proteinases during mouse peri-implantation development: urokinase-type plasminogen activator expression and cross talk with matrix metalloproteinase 9Coordinated induction of extracellular proteolysis systems during experimental autoimmune encephalomyelitis in mice.Activation of the urokinase plasminogen activator/urokinase plasminogen activator receptor system and redistribution of E-cadherin are associated with hepatocyte growth factor-induced motility of pancreas tumor cells overexpressing Met.Changes in procoagulant and fibrinolytic gene expression during bleomycin-induced lung injury in the mouse.Sites of synthesis of urokinase and tissue-type plasminogen activators in the murine kidney.Urokinase-type plasminogen activator-like proteases in teleosts lack genuine receptor-binding epidermal growth factor-like domains.Urokinase-type plasminogen activator is induced in migrating capillary endothelial cellsUpregulation of urokinase receptor expression on migrating endothelial cells.Alterations in plasminogen activation correlate with epithelial cell dysplasia grading in colorectal adenomas.Transforming growth factor beta 1 and sodium butyrate differentially modulate urokinase plasminogen activator and plasminogen activator inhibitor-1 in human breast normal and cancer cellsGain-of-function mutations in the MEC-4 DEG/ENaC sensory mechanotransduction channel alter gating and drug blockadeTissue plasminogen activator-mediated fibrinolysis protects against axonal degeneration and demyelination after sciatic nerve injury.Enhanced tumorigenicity and invasion-metastasis by hepatocyte growth factor/scatter factor-met signalling in human cells concomitant with induction of the urokinase proteolysis networkDeleterious effects of plasminogen activators in neonatal cerebral hypoxia-ischemiaIntegrin-dependent induction of functional urokinase receptors in primary T lymphocytes.Plasminogen activator inhibitor-1 in acute hyperoxic mouse lung injury.Exacerbation of antigen-induced arthritis in urokinase-deficient mice.Modulators of the urokinase-type plasminogen activation system for cancer.Urinary serine proteases and activation of ENaC in kidney--implications for physiological renal salt handling and hypertensive disorders with albuminuria.Variants of tissue-type plasminogen activator with substantially enhanced response and selectivity toward fibrin co-factors.Inhibition of epidermal growth factor-induced invasion by dexamethasone and AP-1 decoy in human squamous cell carcinoma cell lines.Hexamethylene amiloride engages a novel reactive oxygen species- and lysosome-dependent programmed necrotic mechanism to selectively target breast cancer cells.
P2860
Q27622497-B1517F5D-5C88-4EEF-B358-2AC579AEFE35Q28269156-3FBAEAEA-1747-4EF2-8B46-765D495BA57EQ28565213-0A896356-D064-4C3A-B4DA-4A47265BFE15Q28573991-8D077C12-01B7-4E47-985E-19ED50C40385Q30164226-0B3DAFC8-0DB6-4612-8320-005DD3FF0A54Q30303631-52234DCE-7BAA-4EBC-92E3-3BA7925EAD7BQ30470527-A2424E48-6A14-4D14-9A6E-AC00F457B0BEQ33392155-96E82D7E-10C0-4BB1-9387-FC3AB424566BQ34073336-928D81FF-67FB-47D6-8F6F-C735A06C0FFFQ34075065-2D381DD0-D20B-4E25-BAF7-CA151F9F58B1Q34170437-E53C8943-D3AE-4ACE-80FC-C6499DE3456CQ34182861-9E29AC9E-853E-4DCE-BC48-48FDBBB3B638Q34202408-D78D3607-4246-4DD7-BF3E-9940896BA813Q34447297-ABF66860-AB25-4084-BA13-54DE3EDE9717Q34451914-79068AD1-5D29-4EB2-8A3E-13483C75B937Q34473975-B6B3066D-FA4A-47CA-B11D-8F31458C5842Q35069222-4935AA7E-BA03-41E9-837F-A526AC6760F5Q35106632-E07EBFB5-800F-4577-93D6-C80DB35566ADQ35142158-1AF11476-7319-4215-9A7B-4FC8613410F5Q35747177-7096F563-03D9-4B55-BF6E-BB37EEABD6C9Q35753150-0649FC91-6FC5-46A9-9B66-F97307A736BDQ35763567-32F507E6-45C9-4AB1-9F76-8793D9F9423BQ35819933-5187BAE1-F6BF-4FEE-B06E-FDE2704937B4Q36201781-BBDB4F57-BB77-45FA-9BAA-3DF70E900EBCQ36217171-CCC83FD6-8163-46F5-9EB1-0C0BB58EC324Q36232769-314D0869-598B-4403-B96A-6B694A376D97Q36294886-D004FA49-AA6F-407C-B5F8-80B9609512E9Q36295115-0746F6DD-3986-4C76-A82A-C6D45C5C2CD1Q36299668-17F9432F-01F6-40B8-A901-B3D0644B7B04Q36327527-53A39D3B-F243-48EC-AD3E-51FB4743869AQ36557528-6BF57EED-7B1A-4C34-BFEB-FD161FAB17DFQ36691135-E1A2167E-A6E5-4488-960B-49161164A123Q37359182-9808DC97-20EA-4762-9376-4E63DFD751E4Q37362031-7E000319-B660-4AB7-B1E0-DC7538135A0AQ37386932-4DBB19A5-11A7-4CBE-AD61-A5833D4E136AQ37733590-8738CD2A-BA85-4F23-BA64-E102160A4E9FQ38284422-394B7F2C-97B3-4662-A703-EB9084C28E19Q38290601-6BEF643B-DDC7-4CE5-885D-ED197D9905C7Q38361847-98114500-3815-4371-9A6C-DF21C65376C7Q38788869-5514C9F1-9FFD-4E03-A25F-9483A1664239
P2860
Amiloride selectively inhibits the urokinase-type plasminogen activator.
description
1987 nî lūn-bûn
@nan
1987年の論文
@ja
1987年論文
@yue
1987年論文
@zh-hant
1987年論文
@zh-hk
1987年論文
@zh-mo
1987年論文
@zh-tw
1987年论文
@wuu
1987年论文
@zh
1987年论文
@zh-cn
name
Amiloride selectively inhibits the urokinase-type plasminogen activator.
@en
Amiloride selectively inhibits the urokinase-type plasminogen activator.
@nl
type
label
Amiloride selectively inhibits the urokinase-type plasminogen activator.
@en
Amiloride selectively inhibits the urokinase-type plasminogen activator.
@nl
prefLabel
Amiloride selectively inhibits the urokinase-type plasminogen activator.
@en
Amiloride selectively inhibits the urokinase-type plasminogen activator.
@nl
P2860
P1433
P1476
Amiloride selectively inhibits the urokinase-type plasminogen activator.
@en
P2093
P2860
P304
P356
10.1016/0014-5793(87)80039-X
P407
P577
1987-04-01T00:00:00Z